The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
نویسندگان
چکیده
531. Results of a Hepatitis C Virus Screening Program of the 1945-1965 Birth Cohort in a Large Emergency Department in New Jersey Julia Kang Cornett, MD; Vimal Bodiwala, MD; Victor Razuk, BS; Devangi Shukla, BS, MBS and Navaneeth Narayanan, Pharm D, BCPS; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, Department of Pharmacy Practice and Administration, Rutgers Ernest Mario School of Pharmacy, Piscataway, New Jersey
منابع مشابه
الگوهای جدید درمانی برای عفونت ویروس هپاتیت C
Hepatitis C virus (HCV) infection has affected approximately 180 million people across the world. In most cases, HCV-infection remains chronic, which expose patients at high risk of cirrhosis and hepatocellular carcinoma. The rates of disease incidence and mortality diminish as a result of successful treatment of HCV infection. Until the recent years, despite the associated toxicities and l...
متن کاملDirect-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
BACKGROUND AND AIMS Arrival of direct-acting antiviral agents against hepatitis C virus with high-sustained virological response rates and very few side effects has drastically changed the management of hepatitis C virus infection. The impact of direct-acting antiviral exposure on hepatocellular carcinoma recurrence after a first remission in patients with advanced fibrosis remains to be clarif...
متن کاملرویکردهای توسعه واکسن های پیشگیری کننده و درمانی علیه ویروس هپاتیت C
Introdution: An estimated 3% of the world population is chronically infected with hepatitis C virus (HCV), and it is a major health problem that causes cirrhosis and hepatocellular carcinoma. Despite the new directly acting antivirals (DAAs) for curing chronic hepatitis C virus (HCV) infection, the control of the disease has remained a global challenge. Several reasons, including presence of as...
متن کاملHepatic steatosis in HCV-infected persons in the direct-acting antiviral era
Hepatitis C virus (HCV) infects 130-170 million people worldwide. Recently, direct-acting antivirals have been shown to eradicate HCV infection in 90-95 % of non-cirrhotic patients depending on genotype, treatment experience, and regimen used. Similar rates are achieved among compensated cirrhotics, although longer treatment duration and/or ribavirin may be required. HCV uses host lipid metabol...
متن کاملFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
Hepatitis C virus (HCV) infection has been a global health problem for decades, due to the high number of infected people and to the lack of effective and well-tolerated therapies. In the last 3 years, the approval of new direct acting antivirals characterized by high rates of virological clearance and excellent tolerability has dramatically improved HCV infection curability, especially for pat...
متن کاملHepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
Introduction Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma. Explanation Epidemiological studies have indicated that persistent infection with hepatitis C virus...
متن کامل